Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0001437749-18-001223
Filing Date
2018-01-26
Accepted
2018-01-26 16:52:06
Documents
2

Document Format Files

Seq Description Document Type Size
1 FORM 8-K avir20180126_8k.htm 425 34902
2 EXHIBIT 99.1 ex_103708.htm EX-99.1 29449
  Complete submission text file 0001437749-18-001223.txt   66559
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filed by) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 425
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 425 | Act: 34 | File No.: 001-35285 | Film No.: 18552591
SIC: 2836 Biological Products, (No Diagnostic Substances)